The p.T790 M mutation accounted for 50–60% of patients with advanced lung adenocarcinoma (LUAD) and acquired resistance to first or second‐generation epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs).1 Here, EGFR is linked to lung adenocarcinoma.